D-011
1,3-Dinitroglycerin solution
1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C3H6N2O7
Numéro CAS:
Poids moléculaire :
182.09
Numéro CE :
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24
Produits recommandés
Qualité
certified reference material
Forme
liquid
Caractéristiques
Snap-N-Spike®/Snap-N-Shoot®
Conditionnement
ampule of 1 mL
Fabricant/nom de marque
Cerilliant®
Concentration
1.0 mg/mL in acetonitrile
Technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
Application(s)
pharmaceutical (small molecule)
Format
single component solution
Température de stockage
−20°C
Chaîne SMILES
OC(CO[N+]([O-])=O)CO[N+]([O-])=O
InChI
1S/C3H6N2O7/c6-3(1-11-4(7)8)2-12-5(9)10/h3,6H,1-2H2
Clé InChI
ASIGVDLTBLZXNC-UHFFFAOYSA-N
Vous recherchez des produits similaires ? Visite Guide de comparaison des produits
Description générale
1,3-Dinitroglycerin is a major plasma metabolite of the pharmaceutical vasodilator nitroglycerin. This Certified Spiking Solution® is suitable for use in chromatography or mass spectrometry-based applications in pharmaceutical research or clinical toxicology. Nitroglycerin is used to treat heart conditions such as angina and chronic heart failure.
Application
- Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system: This study presents a comprehensive analysis on the population pharmacokinetics of nitroglycerin, focusing on its behavior and the behavior of its metabolites following the use of a transdermal delivery system. The findings contribute to understanding the systemic availability and action of nitroglycerin from such systems, which could be relevant for 1,3-Dinitroglycerin given its structural and functional similarities (Auclair et al., 1998).
- Novel pharmacokinetic modelling of transdermal nitroglycerin: This research explores advanced pharmacokinetic models that describe the absorption and action of nitroglycerin when administered through transdermal patches. Such models are crucial for developing effective transdermal delivery systems for similar compounds like 1,3-Dinitroglycerin (Auclair et al., 1998).
- Bioequivalence Comparison of Two Drug-in-Adhesive Transdermal Nitroglycerin Patches: This study compares the bioequivalence of two transdermal patches delivering nitroglycerin, highlighting the critical factors in the design and performance of transdermal systems that could similarly apply to 1,3-Dinitroglycerin (Harrison et al., 1996).
- Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis: Directly relevant to 1,3-Dinitroglycerin, this study examines its percutaneous absorption characteristics, offering insights into its potential applications in transdermal delivery systems (Ogiso et al., 1990).
- Analysis of solutions containing glutathione and inorganic nitrite: application to nitroglycerin metabolism studies: While primarily focused on nitroglycerin, this analysis could provide secondary insights into the metabolic pathways and interactions of 1,3-Dinitroglycerin with biomolecules like glutathione, which is crucial for understanding its pharmacological effects (Curry et al., 1987).
Informations légales
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Mention d'avertissement
Danger
Mentions de danger
Classification des risques
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2
Code de la classe de stockage
3 - Flammable liquids
Classe de danger pour l'eau (WGK)
WGK 2
Point d'éclair (°F)
35.6 °F - closed cup
Point d'éclair (°C)
2 °C - closed cup
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
N Higo et al.
Pharmaceutical research, 9(2), 187-190 (1992-02-01)
The metabolism of nitroglycerin (GTN) to 1,2- and 1,3-glyceryl dinitrate (GDN) by hairless mouse skin in vitro has been measured. In the first set of experiments, GTN was incubated with the 9000g supernatant of fresh, homogenized tissue in the presence
F W Lee et al.
Journal of pharmacokinetics and biopharmaceutics, 21(5), 533-550 (1993-10-01)
Intravenous infusions of nitroglycerin (GTN), 1,2-glyceryl dinitrate (1,2-GDN), and 1,3-glyceryl dinitrate (1,3-GDN) were given to four conscious dogs at 10 micrograms/min, 30 micrograms/min, 50 micrograms/min, and 70 micrograms/min of GTN and 20 micrograms/min and 100 micrograms/min of GDNs. The steady
M V Wenzl et al.
British journal of pharmacology, 156(8), 1248-1255 (2009-03-04)
Vascular tolerance to nitroglycerin (GTN) may be caused by impaired GTN bioactivation due to inactivation of mitochondrial aldehyde dehydrogenase (ALDH2). As relaxation to GTN is reduced but still sensitive to ALDH2 inhibitors in ascorbate deficiency, we compared the contribution of
Magnus Petersson et al.
Clinical physiology and functional imaging, 28(4), 229-234 (2008-04-04)
Patients with chronic heart failure (CHF) often require higher doses of nitroglycerin (glyceryl trinitrate, GTN) than patients with normal cardiac function to achieve a given haemodynamic goal. Two pathways leading to biotransformation of GTN have been characterized; a high-affinity pathway
W E Haefeli et al.
Clinical pharmacology and therapeutics, 52(6), 590-596 (1992-12-01)
Independent of the route of nitroglycerin administration, substantial amounts of 1,2-glyceryl dinitrate (1,2-GDN) and 1,3-glyceryl dinitrate (1,3-GDN) metabolites accumulate in humans. Thus far their pharmacologic activity in comparison to nitroglycerin in humans is unknown. To compare the venodilatory potency of
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique